Atlas Trials

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Clinical trial NCT03207191 · COMPLETED

Trial details

NCT number
NCT03207191
Sponsor
Philogen S.p.A.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Myeloid Leukemia (AML) Relapse
Start date
2016-12-02
Primary completion
2020-03-26
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.